Yamaguchi Masafumi, Edagawa Makoto, Suzuki Yuzo, Toyozawa Ryo, Hirai Fumihiko, Nosaki Kaname, Seto Takashi, Takenoyama Mitsuhiro, Ichinose Yukito
Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.
Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.
Ann Thorac Surg. 2017 May;103(5):1594-1599. doi: 10.1016/j.athoracsur.2016.08.098. Epub 2016 Nov 15.
We wanted to assess the efficacy of curative intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with synchronous M1b-distant metastases in a single organ or lesion.
Between 1995 and 2015, 23 consecutive synchronous M1b-cStage IV NSCLC patients who underwent any treatment for metastases and curative intent pulmonary resection were retrospectively analyzed.
Sixteen patients were men and 7 were women, with a median age of 56 years (range: 41 to 76 years). There were 17 adenocarcinoma, 4 large-cell carcinoma, 1 large-cell neuroendocrine cancer, and 1 carcinosarcoma. Thirteen patients had no lymph node metastasis. Fourteen patients received preoperative chemotherapy, and 10 received postoperative chemotherapy. The metastatic sites were the brain in 13 patients; bone in 3 patients; adrenal glands and extrathoracic lymph nodes in 2 patients each; and the liver, small intestine, and subcutaneous tissue in 1 patient each. Nineteen patients underwent lobectomy, and the other 4 patients underwent pneumonectomy. Seventeen patients experienced recurrence as follows: local recurrence in 3 patients, distant recurrence in 13 patients, and both in 1 patient. The 5-year progression-free survival rates in the 23 patients was14.5% (95% confidence interval: 0% to 30.6%), and the 5-year overall survival rate was 41.7% (95% confidence interval: 19.6% to 63.8%).
Some M1b-cStage IV NSCLC patients achieved longer survival than others with the same stage disease by using local treatment for distant metastases and curative intent pulmonary resection. Oligometastatic patients might have been inadvertently included in the present cohort. However, at present, the optimum method for patient selection remains unclear.
我们旨在评估对单个器官或病灶发生同步M1b - 远处转移的非小细胞肺癌(NSCLC)患者进行根治性肺切除术的疗效。
回顾性分析了1995年至2015年间连续23例接受过转移灶治疗及根治性肺切除术的同步M1b - c期IV期NSCLC患者。
16例为男性,7例为女性,中位年龄56岁(范围:41至76岁)。其中腺癌17例,大细胞癌4例,大细胞神经内分泌癌1例,癌肉瘤1例。13例患者无淋巴结转移。14例患者接受了术前化疗,10例接受了术后化疗。转移部位为脑13例;骨3例;肾上腺和胸外淋巴结各2例;肝、小肠和皮下组织各1例。19例行肺叶切除术,另外4例行全肺切除术。17例患者出现复发,其中局部复发3例,远处复发13例,两者均有1例。23例患者的5年无进展生存率为14.5%(95%置信区间:0%至30.6%),5年总生存率为41.7%(95%置信区间:19.6%至63.8%)。
部分M1b - c期IV期NSCLC患者通过对远处转移灶进行局部治疗及根治性肺切除术,生存期长于同阶段的其他患者。本队列中可能无意中纳入了寡转移患者。然而,目前患者选择的最佳方法仍不明确。